scholarly journals Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation: A sign of impaired  -cell function?

Diabetes Care ◽  
2006 ◽  
Vol 29 (5) ◽  
pp. 1031-1038 ◽  
Author(s):  
M. Stadler ◽  
C. Anderwald ◽  
T. Karer ◽  
A. Tura ◽  
T. Kastenbauer ◽  
...  
Keyword(s):  
Pancreas Transplantation ◽  
Cell Function ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

Postabsorptive muscle protein metabolism in type 1 diabetic patients after pancreas transplantation

2000 ◽  
Vol 37 (4) ◽  
pp. 219-224 ◽  
Author(s):  
L. Luzi ◽  
L. Piceni Sereni ◽  
M. Spessot ◽  
R. Dodesini ◽  
M.R. Pastore ◽  
...  
Keyword(s):  
Protein Metabolism ◽  
Pancreas Transplantation ◽  
Muscle Protein ◽  
Diabetic Patients ◽  
Muscle Protein Metabolism ◽  
Type 1 Diabetic Patients

Kidney-Pancreas Transplantation Is Associated With Near-Normal Sexual Function in Uremic Type 1 Diabetic Patients

2011 ◽  
Vol 92 (7) ◽  
pp. 802-808 ◽  
Author(s):  
Andrea Salonia ◽  
Francesca DʼAddio ◽  
Chiara Gremizzi ◽  
Alberto Briganti ◽  
Federico Dehò ◽  
...  
Keyword(s):  
Sexual Function ◽  
Pancreas Transplantation ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

AMELIORATION OF HAEMOSTATIC ABNORMALITIES IN UREMIC TYPE 1 DIABETIC PATIENTS AFTER KIDNEY-PANCREAS TRANSPLANTATION

2003 ◽  
Vol 76 (Supplement) ◽  
pp. S44
Author(s):  
PAOLO FIORINA ◽  
FRANCO FOLLI ◽  
CARLO FEDELI ◽  
GIOVANNA FINZI ◽  
CLAUDIA PLACIDI ◽  
...  
Keyword(s):  
Pancreas Transplantation ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

scholarly journals Normalization of Multiple Hemostatic Abnormalities in Uremic Type 1 Diabetic Patients After Kidney-Pancreas Transplantation

Diabetes ◽  
2004 ◽  
Vol 53 (9) ◽  
pp. 2291-2300 ◽  
Author(s):  
P. Fiorina ◽  
F. Folli ◽  
A. D'Angelo ◽  
G. Finzi ◽  
F. Pellegatta ◽  
...  
Keyword(s):  
Pancreas Transplantation ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

Results after 13 years of kidney-pancreas transplantation in type 1 diabetic patients in Comunidad Valenciana

2021 ◽  
Author(s):  
María Argente-Pla ◽  
Antonio Martínez-Millana ◽  
Jordi Espí-Reig ◽  
Javier Maupoey-Ibáñez ◽  
Ángel Moya-Herráiz ◽  
...  
Keyword(s):  
Pancreas Transplantation ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

scholarly journals Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients

2010 ◽  
Vol 24 (4) ◽  
pp. 875-875
Author(s):  
Urd Kielgast ◽  
Meena Asmar ◽  
Sten Madsbad ◽  
Jens J. Holst
Keyword(s):  
Insulin Secretion ◽  
Cell Function ◽  
Glucagon Secretion ◽  
Diabetic Patients ◽  
Β Cell ◽  
C Peptide ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Type 1 Diabetic Patients

Abstract Context: The mechanism by which glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion is uncertain, and it is not determined whether endogenous insulin is a necessary factor for this effect. Objective: Our objective was to characterize the α- and β-cell responses to GLP-1 in type 1 diabetic patients without residual β-cell function. Methods: Nine type 1 diabetic patients, classified as C-peptide negative by a glucagon test, were clamped at plasma glucose of 20 mmol/liter for 90 min with arginine infusion at time 45 min and concomitant infusion of GLP-1 (1.2 pmol/kg · min) or saline. Results: Infusion with GLP-1 increased C-peptide concentration just above the detection limit of 33 pmol/liter in one patient, but C-peptide remained immeasurable in all other patients. In the eight remaining patients, total area under the curve of glucagon was significantly decreased with GLP-1 compared with saline: 485 ± 72 vs. 760 ± 97 pmol/liter · min (P < 0.001). In addition, GLP-1 decreased the arginine-stimulated glucagon release (incremental AUC of 103 ± 21 and 137 ± 16 pmol/liter · min, with GLP-1 and saline, respectively, P < 0.05). Conclusions: In type 1 diabetic patients without endogenous insulin secretion, GLP-1 decreases the glucagon secretion as well as the arginine-induced glucagon response during hyperglycemia. GLP-1 induced endogenous insulin secretion in one of nine type 1 diabetic patients previously classified as being without endogenous insulin secretion.

scholarly journals Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual  -Cell Function

Diabetes ◽  
2011 ◽  
Vol 60 (5) ◽  
pp. 1599-1607 ◽  
Author(s):  
U. Kielgast ◽  
J. J. Holst ◽  
S. Madsbad
Keyword(s):  
Cell Function ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

scholarly journals Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients

2010 ◽  
Vol 95 (5) ◽  
pp. 2492-2496 ◽  
Author(s):  
Urd Kielgast ◽  
Meena Asmar ◽  
Sten Madsbad ◽  
Jens J. Holst
Keyword(s):  
Insulin Secretion ◽  
Cell Function ◽  
Glucagon Secretion ◽  
Diabetic Patients ◽  
Β Cell ◽  
C Peptide ◽  
Endogenous Insulin Secretion ◽  
Endogenous Insulin ◽  
Type 1 Diabetic Patients

Abstract Context: The mechanism by which glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion is uncertain, and it is not determined whether endogenous insulin is a necessary factor for this effect. Objective: To characterize the α- and β-cell responses to GLP-1 in type 1 diabetic patients without residual β-cell function. Methods: Nine type 1 diabetic patients, classified as C-peptide negative by a glucagon test, were clamped at plasma glucose of 20 mmol/liter for 90 min with arginine infusion at time 45 min and concomitant infusion of GLP-1 (1.2 pmol/kg · min) or saline. Results: Infusion with GLP-1 increased C-peptide concentration just above the detection limit of 33 pmol/liter in one patient, but C-peptide remained immeasurable in all other patients. In the eight remaining patients, total area under the curve of glucagon was significantly decreased with GLP-1 compared with saline: 485 ± 72 vs. 760 ± 97 pmol/liter · min (P < 0.001). In addition, GLP-1 decreased the arginine-stimulated glucagon release (incremental AUC of 103 ± 21 and 137 ± 16 pmol/liter · min, with GLP-1 and saline, respectively, P < 0.05). Conclusions: In type 1 diabetic patients without endogenous insulin secretion, GLP-1 decreases the glucagon secretion as well as the arginine-induced glucagon response during hyperglycemia. GLP-1 induced endogenous insulin secretion in one of nine type 1 diabetic patients previously classified as being without endogenous insulin secretion.

Sign in / Sign up

Export Citation Format

Share Document